Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience
Background: Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an effective treatment for advanced HCC. In this study, we present our single-center experience of implementing combined sorafenib and HAIC treatment for these patients and compare the treatment benefit with that of sora...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/5/1887 |
| _version_ | 1797615058189025280 |
|---|---|
| author | Chia-Bang Chen Chun-Min Chen Ruo-Han Tzeng Chen-Te Chou Pei-Yuan Su You-Chuen Hsu Cheng-Da Yang |
| author_facet | Chia-Bang Chen Chun-Min Chen Ruo-Han Tzeng Chen-Te Chou Pei-Yuan Su You-Chuen Hsu Cheng-Da Yang |
| author_sort | Chia-Bang Chen |
| collection | DOAJ |
| description | Background: Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an effective treatment for advanced HCC. In this study, we present our single-center experience of implementing combined sorafenib and HAIC treatment for these patients and compare the treatment benefit with that of sorafenib alone. Methods: This was a retrospective single-center study. Our study included 71 patients who started taking sorafenib between 2019 and 2020 at Changhua Christian Hospital in order to treat advanced HCC or as a salvage treatment after the failure of a previous treatment for HCC. Of these patients, 40 received combined HAIC and sorafenib treatment. The efficacy of sorafenib alone or in combination with HAIC was measured in regard to overall survival and progression-free survival. Multivariate regression analysis was performed to identify factors associated with overall survival and progression-free survival. Results: HAIC combined with sorafenib treatment and sorafenib alone resulted in different outcomes. The combination treatment resulted in a better image response and objective response rate. Moreover, among the patients aged under 65 years old and male patients, the combination therapy resulted in a better progression-free survival than sorafenib alone. A tumor size ≥ 3 cm, AFP > 400, and ascites were associated with a poor progression-free survival among young patients. However, the overall survival of these two groups showed no significant difference. Conclusions: Combined HAIC and sorafenib treatment showed a treatment effect equivalent to that of sorafenib alone as a salvage treatment modality used to treat patients with advanced HCC or with experience of a previously failed treatment. |
| first_indexed | 2024-03-11T07:21:06Z |
| format | Article |
| id | doaj.art-f7c74fa0e96849d59ba5e84be666c334 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T07:21:06Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-f7c74fa0e96849d59ba5e84be666c3342023-11-17T07:59:41ZengMDPI AGJournal of Clinical Medicine2077-03832023-02-01125188710.3390/jcm12051887Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center ExperienceChia-Bang Chen0Chun-Min Chen1Ruo-Han Tzeng2Chen-Te Chou3Pei-Yuan Su4You-Chuen Hsu5Cheng-Da Yang6Department of Medical Imaging, Changhua Christian Hospital, Changhua 500, TaiwanBig Data Center, Changhua Christian Hospital, Changhua 500, TaiwanDepartment of Hematology, Changhua Christian Hospital, Changhua 500, TaiwanDepartment of Medical Imaging, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, TaiwanDivision of Gastroenterology & Hepatology, Changhua Christian Hospital, Changhua 500, TaiwanBackground: Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an effective treatment for advanced HCC. In this study, we present our single-center experience of implementing combined sorafenib and HAIC treatment for these patients and compare the treatment benefit with that of sorafenib alone. Methods: This was a retrospective single-center study. Our study included 71 patients who started taking sorafenib between 2019 and 2020 at Changhua Christian Hospital in order to treat advanced HCC or as a salvage treatment after the failure of a previous treatment for HCC. Of these patients, 40 received combined HAIC and sorafenib treatment. The efficacy of sorafenib alone or in combination with HAIC was measured in regard to overall survival and progression-free survival. Multivariate regression analysis was performed to identify factors associated with overall survival and progression-free survival. Results: HAIC combined with sorafenib treatment and sorafenib alone resulted in different outcomes. The combination treatment resulted in a better image response and objective response rate. Moreover, among the patients aged under 65 years old and male patients, the combination therapy resulted in a better progression-free survival than sorafenib alone. A tumor size ≥ 3 cm, AFP > 400, and ascites were associated with a poor progression-free survival among young patients. However, the overall survival of these two groups showed no significant difference. Conclusions: Combined HAIC and sorafenib treatment showed a treatment effect equivalent to that of sorafenib alone as a salvage treatment modality used to treat patients with advanced HCC or with experience of a previously failed treatment.https://www.mdpi.com/2077-0383/12/5/1887hepatocellular carcinomahepatic arterial infusion chemotherapysorafenib |
| spellingShingle | Chia-Bang Chen Chun-Min Chen Ruo-Han Tzeng Chen-Te Chou Pei-Yuan Su You-Chuen Hsu Cheng-Da Yang Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience Journal of Clinical Medicine hepatocellular carcinoma hepatic arterial infusion chemotherapy sorafenib |
| title | Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience |
| title_full | Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience |
| title_fullStr | Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience |
| title_full_unstemmed | Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience |
| title_short | Combining HAIC and Sorafenib as a Salvage Treatment for Patients with Treatment-Failed or Advanced Hepatocellular Carcinoma: A Single-Center Experience |
| title_sort | combining haic and sorafenib as a salvage treatment for patients with treatment failed or advanced hepatocellular carcinoma a single center experience |
| topic | hepatocellular carcinoma hepatic arterial infusion chemotherapy sorafenib |
| url | https://www.mdpi.com/2077-0383/12/5/1887 |
| work_keys_str_mv | AT chiabangchen combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT chunminchen combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT ruohantzeng combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT chentechou combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT peiyuansu combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT youchuenhsu combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience AT chengdayang combininghaicandsorafenibasasalvagetreatmentforpatientswithtreatmentfailedoradvancedhepatocellularcarcinomaasinglecenterexperience |